Restricted accessResearch articleFirst published online 2010-9
OBSERVE-5,an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies
OBSERVE-5 is collecting safety data from real-world use of etanercept in the treatment of psoriasis per a post-marketing commitment of the U.S. Food and Drug Administration.
Methods
This phase IV prospective, multicenter, 5-year observational registry was designed to enroll patients with plaque psoriasis for whom etanercept is indicated. Patients receive etanercept per standard medical care and can discontinue etanercept therapy at any time following receipt of the baseline dose. Visits occur at least twice yearly; follow-up will be up to 5 years.
Conclusions
Data from the OBSERVE-5 registry will complement safety data from clinical trials of etanercept.
Schmitt-EgenolfM.Psoriasis therapy in real life: the need for registries. Dermatology.2006; 213: (4): 327–30.
3.
AkobengA.K.Assessing the validity of clinical trials. J Pediatr Gastroenterol Nutr.2008; 47: (3): 277–82.
4.
ElewskiB., LeonardiC., GottliebA., StroberB.Sustained long-term clinical efficacy and safety for up to 2.5 years of etanercept in patients with psoriasis. J Am Acad Dermatol.2006; 54(3): AB225.
5.
FinlayA.Y., KhanG.K.Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol.1994; 19(3): 210–6.
6.
ShikiarR., WillianM.K., OkunM.M., ThompsonC.S., RevickiD.A.The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health and Quality of Life Outcomes.2006; 4: 71.
7.
EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy.1990; 16(3): 199–208.
8.
GelfandJ.M., KimballA.B., MostowE.N., ChiouC.F., PatelV., XiaH.A.Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health.2008; 11(3): 400–7.
9.
National Cancer Institute, Division of Cancer Control & Population Sciences, Surveillance Research Program, Cancer Statistics Branch, Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER *Stat Database: Incidence—SEER 9 Regs Public-Use, Nov 2003 Sub (1973–2001), re leased April 2004.
10.
LecluseL.L., NaldiL., SternR.S., SpulsP.I.National registries of systemic treatment for psoriasis and the European ‘Psonet’ initiative. Dermatology.2009; 218(4): 347–56.
11.
Schmitt-EgenolfM.PsoReg—the Swedish registry for systemic psoriasis treatment: the registry's design and objectives. Dermatology.2007; 214(2): 112–7.
12.
NijstenT., WakkeeM.Psocare: Italy shows the way in postmarketing studies. Dermatology.2008; 217(4): 362–4.
13.
Biobadaderm. Academia Española de Dermatología y Venereología and Agencia Española de Medicamentos y Productos Sanitarios. Available at: http://biobadaser.ser.es/biobadaderm/. Accessed 6 October 2009.
14.
British Association of Dermatologists' Biologics Intervention Register (BADBIR)British Association of Dermatologists. Available at: http://www.badbir.org/index.asp. Accessed 6 October 2009.
15.
ChangC.C., GangaramH.B., HusseinS.H.Malaysian Psoriasis Registry–preliminary report of a pilot study using a newly revised registry form. Med J Malaysia.2008; 63(Suppl C): 68–71.
16.
GladmanD.D., RahmanP., KruegerG.G., MeaseP.J., QureshiA.A., DutzJ.P.Clinical and genetic registries in psoriatic disease. J Rheumatol.2008; 35(7): 1458–63.
